Skip to main content
. 2019 Apr 2;20(7):1629. doi: 10.3390/ijms20071629

Figure 5.

Figure 5

Incubation of 3D multilineage spheroids with liraglutide or elafibranor results in a reduction of intra-spheroid fat content. Prevention of steatosis by co-treatment with (A) Liraglutide (1, 10 and 20 μM), (B) Elafibranor (10, 25, 50 μM), (C) vitamin E (10, 25, 50 μM) or (D) obeticholic acid (10, 25, 50 μM) for 48 h in the presence of 500 μM free fatty acids (PAOA) bound to BSA 1%. On the left panels, lipid levels were quantified using AdipoRed biochemical quantification assay. On the right panels cellular ATP levels, normalized to spheroids volumes, remained stable throughout 48 h of treatment (n = 3). Bars represent mean ± SD. P-value was calculated by Mann-Whitney non-parametric test, (* p < 0.05 vs. PAOA 500 μM; # p < 0.005 vs. BSA 1%). BSA: bovine serum albumin; PAOA: palmitic acid/oleic acid.